HCAR2 and myeloid sarcoma: In this study, we investigated which signaling pathways activated by MMF binding to HCAR2 can underlie the contrasting anti- and pro-inflammatory effects of the drug, under different in-vitro and in-vivo conditions and in different cell types relevant to DMF effect in MS.